, Tracking Stock Market Picks
Enter Symbol:

up 8.43 %

MEDIVATION INC (MDVN) rated Buy with price target $100 by Brean Capital

Posted on: Wednesday,  Jan 29, 2014  10:25 AM ET by Brean Capital

Brean Capital rated Buy MEDIVATION INC (NASDAQ: MDVN) on 01/29/2014, when the stock price was $84.91. Since
then, MEDIVATION INC has gained 8.43% as of 01/27/2016's recent price of $92.07.
If you would have followed this Brean Capital's recommendation on MDVN, you would have gained 8.43% of your investment in 728 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Brean Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/29/2014 10:25 AM Buy
84.91 100.00
as of 10/17/2014
1 Week up  1.36 %
1 Month down  -3.76 %
3 Months up  35.48 %
1 YTD up  11.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy